Egyptian International Pharmaceutical Industries Company (EIPICO) - Company Profile

EIPICO was established in Tenth of Ramadan City in 1980, with a capital of EGP 7 Million, currently raised to EGP 1500 Million, as an Egyptian public shareholder company operating according to the Investment Law (No. 43/1974 modified by Law No. 32/1977). 

EIPICO started production in 1985 as the Leading Company in Egypt and in the Middle East and North Africa (MENA) Region, to produce pharmaceutical products according to Good Manufacturing Practice (G.M.P.) regulations, with the aim of providing local and international markets with high-quality products at affordable prices. 

EIPICO is unique with its 9 Sterile Products Areas, which are the Largest and the Most Advanced, in Egypt and in the Middle East and North Africa (MENA) Region. EIPICO has the First Biotechnology and Genetic Engineering Research Center in Egypt manufacturing biopharmaceutical products.

EIPICO manufactures More than 400 Pharmaceutical Products covering 25 Therapeutic Groups. 

EIPICO holds License Agreements with a group of International Pharmaceutical Companies to produce their products locally. 

EIPICO is currently the Major Provider of Antibiotics, Lyophilized Products and Spansule Capsules, to the Egyptian market. 

EIPICO is ranked Number 1 in the Egyptian Ophthalmic Market, by Units.

EIPICO is the Leading Company to Export Pharmaceutical Products.EIPICO currently exports its products to More than 65 Countries around the world, including European, African, Asian, Latin American and CIS (Commonwealth of Independent States) Countries, with 29% Market Share of Egypt’s Total Pharmaceutical Products' Exports. 

In 2014, the World Health Organization accredited EIPICO, as an approved supplier of one type of sterile antibiotic products, being the First Company in Egypt and the Middle East Region.